---
schema_version: "secwatch.filing_event.v1"
accession: "0001386570-25-000025"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:34:23.273984+00:00"
event_type: "other"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Niagen Bioscience authorizes $10M share repurchase program through October 2027

## Summary
- Board authorized up to $10M in common stock repurchases over ~2 years; expires Oct 31, 2027.
- Repurchases may occur in open market or private negotiations; no obligation to buy any shares.
- CEO Rob Fried states company is "an excellent investment" and program is compelling use of capital.
- Program may be modified, suspended, or terminated at any time at Board's discretion.

## SEC filing metadata
- accession: 0001386570-25-000025
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: other
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000138657025000025/0001386570-25-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000138657025000025/cdxc-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001386570-25-000025
- JSON: https://secwatch.observer/filing/0001386570-25-000025.json
- Plain text: https://secwatch.observer/filing/0001386570-25-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.